Who are Red Yeast Rice Pill's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Crestor, Lipitor, Lescol, FLUVASTATIN SODIUM, Ezetimibe/Rosuvastatin, Simvastatin (Zocor).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/red-yeast-rice-pill.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Red Yeast Rice Pill — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Red Yeast Rice Pill (Red Yeast Rice Pill) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Statin (natural/herbal). Area: Cardiovascular.

marketed Statin (natural/herbal) HMG-CoA reductase Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Red Yeast Rice Pill (Red Yeast Rice Pill) — Shiraz University of Medical Sciences. Red yeast rice contains naturally occurring statins that inhibit HMG-CoA reductase, reducing cholesterol synthesis in the liver.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Red Yeast Rice Pill TARGET	Red Yeast Rice Pill	Shiraz University of Medical Sciences	marketed	Statin (natural/herbal)	HMG-CoA reductase
Crestor	rosuvastatin	AstraZeneca	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	2003-01-01
Lipitor	atorvastatin	Pfizer Inc.	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	1996-12-17
Lescol	FLUVASTATIN	Novartis	marketed	HMG-CoA Reductase Inhibitor	HMG-CoA reductase	1993-01-01
FLUVASTATIN SODIUM	FLUVASTATIN SODIUM		marketed		HMG-CoA reductase	1993-01-01
Ezetimibe/Rosuvastatin	Ezetimibe/Rosuvastatin	Addpharma Inc.	marketed	Cholesterol absorption inhibitor + HMG-CoA reductase inhibitor (statin combination)	NPC1L1 transporter (ezetimibe); HMG-CoA reductase (rosuvastatin)
Simvastatin (Zocor)	Simvastatin (Zocor)	New York State Psychiatric Institute	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2037-06-07 — Lipitor · 11654106 · US
2037-06-07 — Lipitor · 11369567 · US

Sponsor landscape (Statin (natural/herbal) class)

Shiraz University of Medical Sciences · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Red Yeast Rice Pill — Competitive Intelligence Brief. https://druglandscape.com/ci/red-yeast-rice-pill. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab